Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nephrotoxicity of vancomycin alone versus vancomycin + piperacillin/tazobactam in pediatric inpatients
ChiCTR-OPC-15006125Phase 4Not yet recruiting
- Sponsor
- Children's Hospital of Fudan University
- Start
- Mar 2015
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of vancomycin and piperacillin + tazobactam in Infection (2 arms), sponsored by Children's Hospital of Fudan University. Primary endpoint: Nephrotoxicity. Planned start Mar 2015; status: not yet recruiting.
02
Drugs
vancomycinpiperacillin + tazobactam
03
Conditions
Infection
Beyond the preview
Go deeper on ChiCTR-OPC-15006125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-15006125.